摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-acetylaminodibenzothiophene triflate | 881375-89-9

中文名称
——
中文别名
——
英文名称
1-acetylaminodibenzothiophene triflate
英文别名
(1-Acetamidodibenzothiophen-4-yl) trifluoromethanesulfonate
1-acetylaminodibenzothiophene triflate化学式
CAS
881375-89-9
化学式
C15H10F3NO4S2
mdl
——
分子量
389.376
InChiKey
HTRDMSULHPPLRL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    109
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    1-acetylaminodibenzothiophene triflate2-morpholin-4-yl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-chromen-4-one四(三苯基膦)钯 potassium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 反应 12.0h, 生成 8-(1'-acetylaminodibenzothiophen-4'-yl)-2-morpholin-4-yl-chromen-4-one
    参考文献:
    名称:
    [EN] DNA-PK INHIBITORS
    [FR] INHIBITEURS D'ADN-PK
    摘要:
    化合物I的分子式为:及其异构体、盐、溶剂和化学保护形式、以及其前药,其中:R1和R2独立选择氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基,或者与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;Q为-NH-C(=O)-或-O-;Y为可选取代的C1-5烷基;X选自SR3或NR4R5,其中R3,或R4和R5独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R4和R5可以与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;如果Q为-O-,X还被选自-C(=O)-NR6R7,其中R6和R7独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R6和R7可以与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;如果Q为-NH-C(=O)-,-Y-X还可以被选自C1-7烷基。
    公开号:
    WO2006032869A1
  • 作为产物:
    描述:
    4-trifluoromethanesulfonyl-dibenzothiophen-1-ylamine 、 乙酸酐吡啶 作用下, 反应 12.0h, 生成 1-acetylaminodibenzothiophene triflate
    参考文献:
    名称:
    [EN] DNA-PK INHIBITORS
    [FR] INHIBITEURS D'ADN-PK
    摘要:
    化合物I的分子式为:及其异构体、盐、溶剂和化学保护形式、以及其前药,其中:R1和R2独立选择氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基,或者与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;Q为-NH-C(=O)-或-O-;Y为可选取代的C1-5烷基;X选自SR3或NR4R5,其中R3,或R4和R5独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R4和R5可以与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;如果Q为-O-,X还被选自-C(=O)-NR6R7,其中R6和R7独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R6和R7可以与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;如果Q为-NH-C(=O)-,-Y-X还可以被选自C1-7烷基。
    公开号:
    WO2006032869A1
点击查看最新优质反应信息

文献信息

  • Dna-Pk Inhibitors
    申请人:Smith Cameron Murray Graeme
    公开号:US20070238731A1
    公开(公告)日:2007-10-11
    A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R 1 and R 2 are independently selected from hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(═O)— or —O—; Y is an optionally substituted C 1-5 alkylene group; X is selected from SR 3 or NR 4 R 5 , wherein, R 3 or R 4 and R 5 are independently selected from hydrogen, optionally substituted C 1-7 alkyl, C 5-20 aryl, or C 3-20 heterocyclyl groups, or R 4 and R 5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(═O)—NR 6 R 7 , wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C 1-7 alkyl, C 5-20 aryl, or C 3-20 heterocyclyl groups, or R 6 and R 7 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is —NH—C(═O)—, —Y—X may additionally be selected from C 1-7 alkyl.
    化合物I的化学式为:以及其异构体、盐、溶剂合物、化学保护形式和前药,其中:R1和R2独立地选自氢、可选择性地取代的C1-7烷基、C3-20杂环基或C5-20芳基,或者与它们连接的氮原子一起形成具有4至8个环原子的可选择性地取代的杂环环;Q为—NH—C(═O)—或—O—;Y为可选择性地取代的C1-5烷基;X选自SR3或NR4R5,其中,R3或R4和R5独立地选自氢、可选择性地取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R4和R5可以与它们连接的氮原子一起形成具有4至8个环原子的可选择性地取代的杂环环;如果Q为—O—,则X还可以从—C(═O)—NR6R7中选取,其中R6和R7独立地选自氢、可选择性地取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R6和R7可以与它们连接的氮原子一起形成具有4至8个环原子的可选择性地取代的杂环环;如果Q为—NH—C(═O)—,则—Y—X还可以从C1-7烷基中选取。
  • DNA-PK INHIBITORS
    申请人:Smith Graeme Cameron Murray
    公开号:US20080242664A1
    公开(公告)日:2008-10-02
    A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R 1 and R 2 are independently selected from hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(═O)— or —O—; Y is an optionally substituted C 1-5 alkylene group; X is selected from SR 3 or NR 4 R 5 , wherein, R 3 , or R 4 and R 5 are independently selected from hydrogen, optionally substituted C 1-7 alkyl, C 5-20 aryl, or C 3-20 heterocyclyl groups, or R 4 and R 5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(═O)—NR 6 R 7 , wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C 1-7 alkyl, C 5-20 aryl, or C 3-20 heterocyclyl groups, or R 6 and R 7 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is —NH—C(═O)—, —Y—X may additionally be selected from C 1-7 alkyl.
    化合物I的公式:及其异构体、盐、溶剂合物、化学保护形式和其前药,其中:R1和R2独立选择氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基,或者与它们连接的氮原子一起形成一个可选取代的杂环环,该环具有4至8个环原子;Q为—NH—C(═O)—或—O—;Y为可选取代的C1-5烷基;X选自SR3或NR4R5,其中R3或R4和R5独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R4和R5与它们连接的氮原子一起形成一个可选取代的杂环环,该环具有4至8个环原子;如果Q为—O—,则X还选自—C(═O)—NR6R7,其中R6和R7独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R6和R7与它们连接的氮原子一起形成一个可选取代的杂环环,该环具有4至8个环原子;如果Q为—NH—C(═O)—,则—Y—X还可以选自C1-7烷基。
  • US7402607B2
    申请人:——
    公开号:US7402607B2
    公开(公告)日:2008-07-22
  • US7732483B2
    申请人:——
    公开号:US7732483B2
    公开(公告)日:2010-06-08
  • [EN] DNA-PK INHIBITORS<br/>[FR] INHIBITEURS D'ADN-PK
    申请人:KUDOS PHARM LTD
    公开号:WO2006032869A1
    公开(公告)日:2006-03-30
    A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is -NH-C(=O)- or -O-; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is -O-, X is additionally selected from -C(=O)-NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R6 and R7 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is -NH-C(=O)-, -Y-X may additionally be selected from C1-7 alkyl.
    化合物I的分子式为:及其异构体、盐、溶剂和化学保护形式、以及其前药,其中:R1和R2独立选择氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基,或者与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;Q为-NH-C(=O)-或-O-;Y为可选取代的C1-5烷基;X选自SR3或NR4R5,其中R3,或R4和R5独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R4和R5可以与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;如果Q为-O-,X还被选自-C(=O)-NR6R7,其中R6和R7独立选择氢、可选取代的C1-7烷基、C5-20芳基或C3-20杂环基,或者R6和R7可以与它们连接的氮原子一起形成一个可选取代的杂环环,其具有4至8个环原子;如果Q为-NH-C(=O)-,-Y-X还可以被选自C1-7烷基。
查看更多

同类化合物